Red Light Holland Transitions to Rhelion Life Sciences, Emphasizing Psychedelic Drug Discovery and Development

Red Light Holland Evolves Into Rhelion Life Sciences With Strategic Rebranding

On July 17, 2026, Red Light Holland Corp. announced its intention to change its corporate name to Rhelion Life Sciences Corp., marking a new phase as a science-driven natural psychedelic drug discovery and development entity. This rebranding awaits approval from the Canadian Securities Exchange.

The new name reflects the company’s strategic transformation into a clinical and research-led organization. Rhelion plans to leverage Filament’s patented naturally derived psilocybin drug candidate, PEX010, alongside its expanding global network of clinical and compassionate use partners, while advancing an ambitious research and development agenda.

Filament Health Acquisition and Advancement of PEX010

The rebrand follows the company’s completed acquisition of Filament Health Corp., granting access to proprietary drug development technologies and intellectual property. The company has enhanced its pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities to support the development of naturally derived psilocybin and Filament’s patented botanical drug candidate, PEX010.

PEX010 is produced through Filament’s proprietary extraction, purification, and stabilization techniques, delivering a potent, standardized, and patented botanical drug product with consistent composition across all doses, studies, and research sites. This consistency is protected by a broad international patent portfolio and supported by a proven 36-month shelf life.

Expanded Dosing Range and Standardization Efforts

Filament Health recently introduced a 0.5 mg dose of PEX010, complementing existing 1, 5, and 25 mg strengths. This expanded dosing range enables standardized administration from sub-hallucinogenic microdosing to full therapeutic doses. The company emphasizes that PEX010’s reproducibility at scale ensures uniform composition across production batches, allowing researchers to attribute results directly to the compound without batch variability concerns.

This development aligns with growing demand for pharmaceutical-grade, naturally derived psilocybin and strengthens Filament’s role in academic and clinical research. The standardized dosing options support robust operational and quality systems for reliable global supply.

Global Academic and Philanthropic Research Network

PEX010 has been supplied to more than 80 academic and philanthropic research studies worldwide, including institutions such as Imperial College, Johns Hopkins University, University of California San Francisco, and McGill University. This extensive network highlights significant institutional interest in standardized, naturally derived psilocybin for research.

The company actively supports clinical research and compassionate use programs with these leading institutions, which remains central to its strategy under the Rhelion brand.

Sector Growth and Pharmaceutical Industry Engagement

The rebranding coincides with accelerating momentum in the psychedelic sector and increasing investor enthusiasm. Notably, on July 16, 2026, Eli Lilly and Company announced an agreement to acquire AtaiBeckley for up to US$3.8 billion, one of the largest deals in the sector, signaling major pharmaceutical interest in clinically de-risked psychedelic assets.

This sector activity underscores the timing of Rhelion’s rebrand, as the company aims to create de-risked shareholder value amid growing pharmaceutical engagement in psychedelics.

CEO Todd Shapiro Highlights Strategic Vision

Todd Shapiro, CEO and Director, stated the name change "represents everything we have been building toward regarding responsible and standardized psychedelic access—from underground to mainstream." He described the rebrand as embodying the company’s identity as a "science-first, research-driven organization with a world-class drug development platform, a growing program, and a bold vision for natural psychedelic medicine."

Shapiro further emphasized Rhelion Life Sciences’ tagline, "Rediscover Health," focusing on "science-backed innovation aimed at long-term mental wellness and conscious human advancement." This messaging targets patients, researchers, partners, regulators, and both retail and institutional investors.

Enhanced Brand Positioning and Stakeholder Engagement

The company believes the Rhelion brand better communicates its mission across diverse stakeholders compared to its previous identity. The new brand provides a unified platform to advance clinical, research, and commercialization goals globally.

This repositioning aims to strengthen relations with pharmaceutical regulators, academic institutions, and institutional investors, reflecting the company’s specialized focus on drug discovery and clinical research.

Operations in Adult-Use Market Complement Research Initiatives

In addition to drug development, the company operates within the Netherlands’ legal adult-use market and supports voluntary data collection and research to enhance scientific understanding of natural psychedelics. This diversified approach integrates commercial operations with research to inform clinical trial planning and broader strategy.

Name Change Approval and Trading Symbol Updates

The company will provide further details on the name change, including the effective date and any changes to trading symbols, following Canadian Securities Exchange approval. Investors should monitor upcoming announcements for updates on the rebrand’s implementation and related trading symbol modifications.

The new corporate website is www.Rhelion.com. The rebrand remains conditional on CSE approval, with no specific timeline disclosed for the approval or effective date.